These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17503094)

  • 1. A proteomic approach for the identification of bismuth-binding proteins in Helicobacter pylori.
    Ge R; Sun X; Gu Q; Watt RM; Tanner JA; Wong BC; Xia HH; Huang JD; He QY; Sun H
    J Biol Inorg Chem; 2007 Aug; 12(6):831-42. PubMed ID: 17503094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colloidal bismuth subcitrate impedes proton entry into Helicobacter pylori and increases the efficacy of growth-dependent antibiotics.
    Marcus EA; Sachs G; Scott DR
    Aliment Pharmacol Ther; 2015 Oct; 42(7):922-33. PubMed ID: 26238858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: In vitro data Do not predict In vivo efficacy.
    Phillips RH; Whitehead MW; Lacey S; Champion M; Thompson RP; Powell JJ
    Helicobacter; 2000 Sep; 5(3):176-82. PubMed ID: 10971684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
    Park KN; Hahm JS; Kim HJ
    Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A histidine-rich and cysteine-rich metal-binding domain at the C terminus of heat shock protein A from Helicobacter pylori: implication for nickel homeostasis and bismuth susceptibility.
    Cun S; Li H; Ge R; Lin MC; Sun H
    J Biol Chem; 2008 May; 283(22):15142-51. PubMed ID: 18364351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of fumarase by bismuth(III): implications for the tricarboxylic acid cycle as a potential target of bismuth drugs in Helicobacter pylori.
    Chen Z; Zhou Q; Ge R
    Biometals; 2012 Feb; 25(1):95-102. PubMed ID: 21818585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional disruption of peroxiredoxin by bismuth antiulcer drugs attenuates Helicobacter pylori survival.
    Chang YY; Cheng T; Yang X; Jin L; Sun H; Li H
    J Biol Inorg Chem; 2017 Jul; 22(5):673-683. PubMed ID: 28361362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.
    Kung NN; Sung JJ; Yuen NW; Li TH; Ng PW; Lai WM; Lui YH; Lam KN; Choi CH; Leung EM
    Am J Gastroenterol; 1999 Mar; 94(3):721-4. PubMed ID: 10086657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systems Approaches for Unveiling the Mechanism of Action of Bismuth Drugs: New Medicinal Applications beyond Helicobacter Pylori Infection.
    Li H; Wang R; Sun H
    Acc Chem Res; 2019 Jan; 52(1):216-227. PubMed ID: 30596427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The actions of bismuth in the treatment of Helicobacter pylori infections: an update.
    Ge R; Chen Z; Zhou Q
    Metallomics; 2012 Mar; 4(3):239-43. PubMed ID: 22358069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Proteins Related to Nickel Homeostasis in Helicobater pylori by Immobilized Metal Affinity Chromatography and Two-Dimensional Gel Electrophoresis.
    Sun X; Ge R; Chiu JF; Sun H; He QY
    Met Based Drugs; 2008; 2008():289490. PubMed ID: 18288244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Hpn and NixA of Helicobacter pylori in susceptibility and resistance to bismuth and other metal ions.
    Mobley HL; Garner RM; Chippendale GR; Gilbert JV; Kane AV; Plaut AG
    Helicobacter; 1999 Sep; 4(3):162-9. PubMed ID: 10469190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
    Kung NN; Sung JJ; Yuen NW; Ng PW; Wong KC; Chung EC; Lim BH; Choi CH; Li TH; Ma HC; Kwok SP
    Am J Gastroenterol; 1997 Mar; 92(3):438-41. PubMed ID: 9068464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivation of NikR from Helicobacter pylori by a bismuth drug.
    Guo Y; Guan C; Wan H; Zhang Z; Li H; Sun H; Xia W
    J Inorg Biochem; 2019 Jul; 196():110685. PubMed ID: 30999221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined activity of trospectomycin and colloidal bismuth subcitrate against Helicobacter pylori in vitro.
    Vogt K; Rodloff AC; Hahn H
    Infection; 1991; 19(3):138-9. PubMed ID: 1832417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bismuth-mediated disruption of the glycocalyx-cell wall of Helicobacter pylori: ultrastructural evidence for a mechanism of action for bismuth salts.
    Stratton CW; Warner RR; Coudron PE; Lilly NA
    J Antimicrob Chemother; 1999 May; 43(5):659-66. PubMed ID: 10382887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The action of bismuth against Helicobacter pylori mimics but is not caused by intracellular iron deprivation.
    Bland MV; Ismail S; Heinemann JA; Keenan JI
    Antimicrob Agents Chemother; 2004 Jun; 48(6):1983-8. PubMed ID: 15155188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study.
    Ciccaglione AF; Cellini L; Grossi L; Manzoli L; Marzio L
    Helicobacter; 2015 Oct; 20(5):390-6. PubMed ID: 25801708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.